Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$5.38 USD
+0.29 (5.70%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.38 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Xeris Biopharma Holdings, Inc. has a market cap of $796.00M, which represents its share price of $5.09 multiplied by its outstanding shares number of 156.38M. As a small-cap company, XERS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
XERS 5.38 +0.29(5.70%)
Will XERS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XERS
Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
Other News for XERS
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 | XERS Stock News
Rare Stock Picks In June 2025 - From 26 Discerning Analysts
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
Top Executive Makes Bold Move with Major Stock Purchase!
Leerink Partners Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)